{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=8",
    "query": {
      "intervention": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 177,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T01:15:14.097Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00763451",
      "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pen auto-injector",
          "type": "DEVICE"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2008-09",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763451"
    },
    {
      "nct_id": "NCT02846233",
      "title": "Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "GLP1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "basal insulin",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-08",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846233"
    },
    {
      "nct_id": "NCT07760532",
      "title": "Comparing Facial Aging Between Identical Twins With 3D Imaging",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facial Skin Aging",
        "Facial Volume Loss",
        "Wrinkle Appearance"
      ],
      "interventions": [
        {
          "name": "GLP-1 Receptor Agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ponsky Facial Aesthetics And Plastic Surgery, Llc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2026-08-08",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Beachwood, Ohio",
      "locations": [
        {
          "city": "Beachwood",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07760532"
    },
    {
      "nct_id": "NCT07812636",
      "title": "Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Grade 1 Endometrial Endometrioid Carcinoma",
        "Endometrial Intraepithelial Neoplasia",
        "Metabolic Comorbidities"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2026-11-01",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07812636"
    },
    {
      "nct_id": "NCT00713830",
      "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pen auto-injector",
          "type": "DEVICE"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 859,
      "start_date": "2008-07",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713830"
    },
    {
      "nct_id": "NCT03954834",
      "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 478,
      "start_date": "2019-06-03",
      "completion_date": "2020-10-28",
      "has_results": true,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 28,
      "location_summary": "Huntington Park, California • Los Angeles, California • Montclair, California + 24 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954834"
    },
    {
      "nct_id": "NCT06038734",
      "title": "Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Delayed Gastric Emptying",
        "Gastroparesis"
      ],
      "interventions": [
        {
          "name": "gastric ultrasound",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2023-11-10",
      "completion_date": "2024-04-17",
      "has_results": false,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06038734"
    },
    {
      "nct_id": "NCT05071898",
      "title": "Pharmacogenetics of Response to GLP1R Agonists",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Semaglutide Pen Injector [Ozempic]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 600,
      "start_date": "2022-04-11",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05071898"
    },
    {
      "nct_id": "NCT05762744",
      "title": "Pharmacogenomics of GLP1 Receptor Agonists",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide Injection (before the first FSIGT)",
          "type": "DRUG"
        },
        {
          "name": "Exenatide injection before the second FSIGT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2016-06-01",
      "completion_date": "2022-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 1,
      "location_summary": "Lancaster, Pennsylvania",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05762744"
    },
    {
      "nct_id": "NCT06987513",
      "title": "RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder (AUD)"
      ],
      "interventions": [
        {
          "name": "Pemvidutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-15",
      "completion_date": "2026-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-15T01:15:14.097Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "University Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06987513"
    }
  ]
}